Pfizer Vs. Moderna: Which Vaccine Stock Is A Better Investment For The Rest Of 2021?

Image Source: Pexels

New York City-based Pfizer Inc. (PFE) develops, manufactures, markets distributes, and sells biopharmaceutical products worldwide. In addition, the company offers medicines and vaccines in various therapeutic areas. In comparison, Cambridge, Mass.-based Moderna, Inc. (MRNA) is a biotechnology company that develops therapeutics and vaccines based on messenger RNA to treat infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

The biotech and pharma industry thrived amid the COVID-19 pandemic due to substantial capital investments to develop vaccines and therapies for the virus. The industry is expected to remain in focus in the coming months because of the rapid spread of the virus’ Delta variant in several parts of the world. According to a new report by Grand View Research, the global biotechnology market is expected to expand at a 15.83% CAGR from 2021 – 2028. So, both MRNA and PFE are well-positioned to continue benefiting from the industry tailwinds.

MRNA has gained 110.1% over the past six months, while PFE has returned 34.5% over the period. Also, MRNA’s 268.8% gains year-to-date compare with PFE’s 25.8% returns. Furthermore, MRNA is the clear winner with 458.7% gains versus PFE’s 22.6% in terms of the past year’s performance.

But which stock is a better buy now? Let’s find out.

Latest Developments

On July 23, PFE and BioNTech SE (BNTX) announced that the U.S. government had purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This should deliver to the company a continuous stream of revenue over the period.

On August 9, MRNA announced that the Therapeutic Goods Administration (TGA) had granted provisional registration to the COVID-19 Vaccine Moderna in Australia for active immunization. This demonstrates the company’s overseas reach and wide demand for its vaccines.

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.